Rare variants in LRRK1 and Parkinson's disease

Neurogenetics

Volumn 15, Issue 1, 2014, Pages 49-57

  Schulte, Eva C ^a,b   Ellwanger, Daniel C ^c   Dihanich, Sybille ^d   Manzoni, Claudia ^d   Stangl, Katrin ^e   Schormair, Barbara ^b,c   Graf, Elisabeth ^b   Eck, Sebastian ^b   Mollenhauer, Brit ^f,g   Haubenberger, Dietrich ^h   Pirker, Walter ^h   Zimprich, Alexander ^h   Brücke, Thomas ⁱ   Lichtner, Peter ^b,c   Peters, Annette ^b   Gieger, Christian ^b   Trenkwalder, Claudia ^f,g   Mewes, Hans Werner ^c   Meitinger, Thomas ^b,c,j   Lewis, Patrick A ^d,k   Klünemann, Hans H ^e   Winkelmann, Juliane ^a,b,c,j,l   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^f Paracelsus Elena Klinik   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ WILHELMINEN HOSPITAL   (Austria)

^j Germany 3 Munich Cluster for Systems Neurology   (Germany)

^k UNIVERSITY OF READING   (United Kingdom)

^l STANFORD UNIVERSITY   (United States)

more..

Author keywords

EEF1D; Exome sequencing; LRRK1; Parkinson's disease

Indexed keywords

ADULT; AGED; ARTICLE; BIOINFORMATICS; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EEF1D GENE; EXOME; FAMILY STUDY; FEMALE; GENE; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; LRRK1 GENE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEGREGATION ANALYSIS;

ALGORITHMS; CELL SURVIVAL; DNA MUTATIONAL ANALYSIS; EXOME; FAMILY HEALTH; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; GERMANY; HUMANS; MALE; MIDDLE AGED; MODELS, GENETIC; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARKINSON DISEASE; PEPTIDE ELONGATION FACTOR 1; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84897954643     PISSN: 13646745     EISSN: 13646753     Source Type: Journal    
DOI: 10.1007/s10048-013-0383-8     Document Type: Article

References (35)

1. Payami H, Larsen K, Bernard S, Nutt J (1994) Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol 36:659-661
2. Bonifati V, Fabrizio E, Vanacore N, De Mari M, Meco G (1995) Familial Parkinson's disease: a clinical genetic analysis. Can J Neurol Sci 22:272-279
3. Zimprich A, Biskup S, Leitner P et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607
4. Bonifati V, Rizzu P, van Baren MJ et al (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256-259
5. Kitada T, Asakawa S, Hattori N et al (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608
6. Paisan-Ruiz C, Jain S, Evans EW et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600
7. Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047
8. Valente EM, Abou-Sleiman PM, Caputo V et al (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304:1158-1160
9. Zimprich A, Benet-Pages A, Struhal W et al (2011) A Mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 89:168-175
10. Vilarino-Güell C, Wider C, Ross OA et al (2011) VPS35 mutations in Parkinson disease. Am J Hum Genet 89:162-167
11. Wichmann HE, Gieger C, Illig T (2004) KORAgen - resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen 67(Suppl 1):26-30
12. Korr D, Toschi L, Donner P, Pohlenz HD, Kreft B, Weiss B (2006) LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain. Cell Signal 18:910-920
13. Shimodaira H (2004) Approximately unbiased tests of regions using multistep-multiscale bootstrap resampling. Ann Statistics 32:2616-2641
14. Greggio E, Lewis PA, van der Brug MP et al (2007) Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J Neurochem 102:93-102
15. Elbaz A, Bower JH, Maraganore DM et al (2002) Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 55:25-31
16. Chartier-Harlin MC, Dachsel JC, Vilarino-Guell C et al (2011) Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 89:398-406
17. Gehrke S, Imai Y, Sokol N, Lu B (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466:637-641
18. Hanafusa H, Ishikawa K, Kedashiro S et al (2011) Leucine-rich repeat kinase LRRK1 regulates endosomal trafficking of the EGF receptor. Nat Comm 2:158
19. Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361:1651-1661
20. Tong Y, Yamaguchi H, Giaime E et al (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 107:9879-9884
21. Dachsel JC, Nishioka K, Vilarino-Güell C et al (2010) Heterodimerization of Lrrk1-Lrrk2: implications for LRRK2-associated Parkinson disease. Mech Age Dev 131:210-214
22. Klein CL, Rovelli G, Springer W, Schall C, Gasser T, Kahle PJ (2009) Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J Neurochem 111:703-715
23. Deng X, Dzamko N, Prescott A et al (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 7:203-205
24. Civiero L, Vancraenenbroeck R, Belluzzi E et al (2012) Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS One 7:e43472
25. Tennessen JA, Bigham AW, O'Connor T et al (2012) Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 337:64-69
26. Healy DG, Falchi M, O'Sullivan SS et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7:583-590
27. Marin I, van Egmond WN, van Haastert PJM (2008) The Roco protein family: a functional perspective. FASEB 22:3103-3110
28. Whitney IE, Raven MA, Ciobanu DC, Williams RW, Reese BE (2009) Multiple genes on chromosome 7 regulate dopaminergic amacrine cell number in the mouse retina. Invest Ophthal Vis Sci 50:1996-2003
29. Ishikawa K, Nara A, Matsumoto K, Hanafusa H (2012) EGFR-dependent phosphorylation of leucine-rich repeat kinase LRRK1 is important for proper endosomal trafficking of EGFR. Mol Biol Cell 23:1294-1306
30. Gómez-Suaga P, Luzón-Toro B, Churamani D et al (2012) Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet 21:511-525
31. Dodson MW, Zhang T, Jiang C, Chen S, Guo M (2012) Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet 21:1350-1363
32. Haugarvoll K, Toft M, Ross OA, White LR, Aasley JO, Farrer MJ (2007) Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway. Neurosci Lett 416:299-301
33. Chung SJ, Armasu SM, Biernacka JM et al (2011) Common variants in PARK loci and related genes and Parkinson's disease. Mov Disord 26:280-288
34. Taylor JP, Hulihan MM, Kachergus JM et al (2007) Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. Neurogenetics 8:95-102
35. Davis EE, Zhang Q, Liu Q et al (2011) TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. Nat Genet 43:189-196